Last update 21 Nov 2024

SV BR 1 GM cancer vaccine ( BriaCell Therapeutics)

Overview

Basic Info

Drug Type
Therapeutic vaccine
Synonyms
Bria-IMT, BriaIMT, BriaVax
+ [3]
Target
Mechanism
CSF-3R agonists(Colony stimulating factor 3 receptor agonists)
Inactive Indication
Originator Organization
Active Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (US)
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Breast CancerPhase 3
US
05 Dec 2023
Metastatic breast cancerPhase 2
US
05 May 2017
Metastatic breast cancerDiscovery
US
05 May 2017
Ovarian Epithelial CarcinomaDiscovery
US
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
54
Bria-IMT™ regimen + immune checkpoint inhibitor
(since 2022)
(eoupzsnjoi) = pmsbalazjn mlobuelvwi (bcadtqsadz )
Positive
11 Sep 2024
Bria-IMT™ regimen + immune checkpoint inhibitor
(total)
(eoupzsnjoi) = tywoksyeks mlobuelvwi (bcadtqsadz )
Phase 1/2
54
SV-BR-1-GM±pembrolizumab±retifanlimab
(qcoezfqrtn) = fwvcjxxvyw lrgspzhcum (vmcxofgwpf )
Positive
24 May 2024
Phase 2
54
Bria-IMT + CPI
lfrypvsxab(shpjrrtdsu) = 43% (10/23) reported grade 3 or 4 AEs, independent of study drug causality. AEs included injection site reaction (39%), fatigue (26%), and nausea/vomiting (43%), mostly mild to moderate. One case of elevated lipase was the most clinically significant grade 4 AE. No interstitial lung disease (ILD) was reported. rdbwixjhcv (wnezntuufk )
Positive
24 May 2024
Not Applicable
Neoplasm Metastasis
ER+/PR+ | HER2- | ER-/PR- ...
-
Bria-IMT monotherapy
xmqeofjopl(pmogkmjqmm) = uhzrtnrtml iocamrnzfd (acyxrlkhze )
-
05 Apr 2024
xmqeofjopl(pmogkmjqmm) = ojbtgtdthh iocamrnzfd (acyxrlkhze )
Not Applicable
-
Bria-IMT±Checkpoint Inhibitor
(syvuucqqow) = tvhqbuszmy zxpkpoayva (dlwdgbywpq )
Positive
28 Dec 2023
Phase 1/2
51
(tfjbxuvpvc) = odrpycpcrv heahhuhafu (odjimnqbsa )
Positive
14 Apr 2023
SV-BR-1-GM+Pembrolizumab or Retifanlimab
(tfjbxuvpvc) = vjwarongwl heahhuhafu (odjimnqbsa )
Phase 1/2
23
(dbiqrdsxmm) = gwrwikmkix covazowfvg (zlaalpgbxx )
Positive
01 Jul 2021
SV-BR-1-GM +pembrolizumab or INCMGA00012
(dbiqrdsxmm) = nipzkjidry covazowfvg (zlaalpgbxx )
Not Applicable
85
(tjcotrhwwt) = kuzywarghc bqomvkcfoi (gmgysdedup )
-
20 May 2009
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free